Ann Oncol

1. WILCOX JA, Jeng MY, Tischfield S, Sui JSY, et al
   Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases.
   Ann Oncol. 2025;36:1142-1153.
   

   >> Share

   
   

   
   Ann Surg Oncol

2. ZHONG G, Chen Y, Lai H, He J, et al
   Beyond the Scalpel: EGFR Mutation Predicts Intraoperative Blood Loss and Transfusion Needs During Lung Cancer-derived Spinal Metastasis Surgery.
   Ann Surg Oncol. 2025 Sep 23. doi: 10.1245/s10434-025-18332.
   

   >> Share

   
   
3. MOTT NM, Meguid RA, Randhawa SK, David EA, et al
   Social Vulnerability is Associated with Significant Delays to Definitive Surgery for Stages IA to IIIA Non-small Cell Lung Cancer and Consequential Increased Rates of Pathologic Upstaging.
   Ann Surg Oncol. 2025 Sep 20. doi: 10.1245/s10434-025-18337.
   

   >> Share

   
   
4. LOMBARDO J, Florea IB, Toomey N, Khrizman P, et al
   The Landmark Series: Role of Curative Intent Treatment for Oligometastatic Disease of the Lung.
   Ann Surg Oncol. 2025;32:7845-7851.
   

   >> Share

   
   

   
   Ann Thorac Surg

5. WAGEMAKER VIANA S, Van Haren RM
   Bridging the Gap in Lung Cancer Screening: Lessons from a Culturally Tailored Intervention with Lay Navigators.
   Ann Thorac Surg. 2025 Sep 19:S0003-4975(25)00886.
   

   >> Share

   
   

   
   Br J Cancer

6. TAKEZAWA K, Okamoto I, Tsukioka S, Uchida J, et al
   Retraction Note: Identification of thymidylate synthase as a potential therapeutic target for lung cancer.
   Br J Cancer. 2025 Sep 19. doi: 10.1038/s41416-025-03211.
   

   >> Share

   
   
7. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
   Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
   Br J Cancer. 2025;133:874-885.
   

   >> Share

   
   
8. SAKAI SA, Oyoshi H, Nakamura M, Taki T, et al
   Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy.
   Br J Cancer. 2025;133:795-808.
   

   >> Share

   
   

   
   Cancer

9. ISLAMI F, Wiese D, Schafer EJ, Sung H, et al
   Stage-specific cancer survival in Black and White persons by urbanicity of county of residence, United States, 2015-2021.
   Cancer. 2025;131:e70073.
   

   >> Share

   
   

   
   Cancer Res

10. GEBRU MT, Hoffman TE, Boudreau A, Vu N, et al
    Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer.
    Cancer Res. 2025 Sep 18. doi: 10.1158/0008-5472.CAN-24-4887.
    

    >> Share

    
    
11. PAN T, Zhu J, Wang X, Tang D, et al
    MEN1 Promotes Ferroptosis by Disrupting CD44 Alternative Splicing to Suppress Lung Cancer.
    Cancer Res. 2025 Sep 24. doi: 10.1158/0008-5472.CAN-25-0021.
    

    >> Share

    
    

    
    Cancer Sci

12. ZENKE Y, Shiraishi Y, Goto Y, Azuma K, et al
    Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.
    Cancer Sci. 2025 Sep 21. doi: 10.1111/cas.70188.
    

    >> Share

    
    

    
    Clin Lung Cancer

13. MORINAGA D, Furuta M, Morita S, Miyauchi E, et al
    A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2).
    Clin Lung Cancer. 2025 Aug 26:S1525-7304(25)00219.
    

    >> Share

    
    
14. BRAMBILLA M, Barbetta F, Nardo G, Agnelli L, et al
    Refining High-Risk EGFR-Mutant Lung Cancer Patients: The Role of Adjusted Variant Allele Frequency in First-Line Osimertinib Therapy.
    Clin Lung Cancer. 2025 Aug 31:S1525-7304(25)00221.
    

    >> Share

    
    
15. MUDD J, Zafar H, Mhango G, Slatore CG, et al
    Provider Bias in Decision Making About Treatment of Early-stage Lung Cancer With Stereotactic Body Radiation Therapy or Sub-lobar Resection.
    Clin Lung Cancer. 2025 Aug 23:S1525-7304(25)00217.
    

    >> Share

    
    

    
    Eur J Cardiothorac Surg

16. SHIH BC, Jung W, Lee JH, Cho S, et al
    Perineural invasion affects the risk and pattern of recurrence in non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2025 Sep 19:ezaf299. doi: 10.1093.
    

    >> Share

    
    
17. AHMAD M, Saleh MA
    Caution in interpreting lobectomy superiority for centrally located stage i non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2025 Sep 19:ezaf309. doi: 10.1093.
    

    >> Share

    
    
18. RUSCA GIMENEZ M, Gonzalez-Rivas D, Gomez Tabales J, Bosinceanu ML, et al
    Uniportal Robotic-Assisted Sleeve Resection of the Left Main Bronchus and Secondary Carinal Reconstruction for Typical Carcinoid Tumour.
    Eur J Cardiothorac Surg. 2025;67:ezaf280.
    

    >> Share

    
    
19. HE H, Yu C, Yang Y, Maessen JG, et al
    Three-Dimensional Reconstruction and Virtual Simulation of Patient-Specific Anatomy for Procedural Planning in Thoracoscopic Segmentectomy: A Systematic Review and Meta-Analysis.
    Eur J Cardiothorac Surg. 2025;67:ezaf283.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

20. FRIEDES C, Yegya-Raman N, Iocolano M, Levin WP, et al
    Primary Tumor Failure after Definitive Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer: A Brief Report on the Implications for NRG LU-008.
    Int J Radiat Oncol Biol Phys. 2025 Sep 16:S0360-3016(25)06276.
    

    >> Share

    
    

    
    J Immunol

21. KEREMITCI D, Tuna O, Houdjedj A, Kazan H, et al
    Transcriptional states of lung cancer microenvironment reveal macrophage subtype dynamics linked to disease progression.
    J Immunol. 2025 Sep 16:vkaf253. doi: 10.1093.
    

    >> Share

    
    

    
    Lung Cancer

22. RAJARAM R, Huang Q, Johnson BH, Laxmanan B, et al
    Implications of primary tumor size on overall survival in patients with multifocal T3 non-small cell lung cancer.
    Lung Cancer. 2025;208:108746.
    

    >> Share

    
    
23. ZHANG R, Yan H, Tian F, Jiang Y, et al
    Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIs.
    Lung Cancer. 2025;208:108755.
    

    >> Share

    
    
24. IWAMA E, Sakai K, Harada T, Kanda S, et al
    Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations.
    Lung Cancer. 2025;208:108756.
    

    >> Share

    
    
25. TAKEMURA C, Yoshida T, Yoshida Y, Inaba Higashiyama R, et al
    Unveiling the molecular and clinical risk landscape of second primary lung cancer in resected non-small cell lung cancer.
    Lung Cancer. 2025;208:108750.
    

    >> Share

    
    
26. WANG J, Cao H, He N, Liu X, et al
    Evolving Trends in Surgically Managed Lung Cancer: A 16-Year Hospital-Based Epidemiological Analysis.
    Lung Cancer. 2025;208:108754.
    

    >> Share

    
    

    
    Mol Carcinog

27. WANG W, Tian S, Ou Y, Yang J, et al
    FBXW5 Promotes Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Through the KLF13/TROAP Signaling Pathway.
    Mol Carcinog. 2025;64:1638-1649.
    

    >> Share

    
    

    
    Oncogene

28. YANG M, Lu Y, Zheng J, Zhao X, et al
    PRICKLE3-USP9X interaction-mediated DVL2 deubiquitination promotes the progression of non-small cell lung cancer via canonical WNT pathway.
    Oncogene. 2025 Sep 19. doi: 10.1038/s41388-025-03580.
    

    >> Share

    
    

    
    Oncol Rep

29. ZHAO C, Xu Y, Zhang Y, Tan W, et al
    [Expression of Concern] Downregulation of miR?145 contributes to lung adenocarcinoma cell growth to form brain metastases.
    Oncol Rep. 2025;54:158.
    

    >> Share

    
    
30. ZHENG WW, Ding JX, Liang YX, Ye L, et al
    Hydroxypropyl?beta?cyclodextrin/thymoquinone inclusion complex inhibits non?small cell lung cancer progression through NF?kappaB?mediated ferroptosis.
    Oncol Rep. 2025;54:157.
    

    >> Share

    
    

    
    Oncologist

31. LIU Y, Liu F, Wang C, Yan Y, et al
    Clinicopathological and molecular characteristics and treatment outcomes of SMARCA4-deficient thoracic tumors: a comprehensive analysis.
    Oncologist. 2025;30:oyaf266.
    

    >> Share

    
    
32. LISBERG A, Huppert LA, Halmos B, Ledezma B, et al
    Datopotamab deruxtecan-associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management.
    Oncologist. 2025;30:oyaf225.
    

    >> Share

    
    

    
    PLoS One

33. KIZILTAN HS, Cepni K
    Prognostic value of D-dimer in treatment and follow up for patients who underwent radiotherapy in advanced lung cancer.
    PLoS One. 2025;20:e0333085.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share